iAMD progression
iAMD clinical trials
population of iAMD patients
functional assessments
functional impairment
functional tests
conduct of future iAMD CTs
functional outcomes preceding progression
functional decline
successful development of iAMD interventions
delaying progression
rapid progression
significant burden of late stage AMD
novel clinical endpoints
novel functional vision tests
accurate assessment of progression
functional changes meaningful
late stages
late stage age-related macular degeneration
preceding disease stage intermediate AMD
structural assessments
visual impairment
patient preferences
surrogate endpoints
impairment of visual function
structural biomarkers
novel interventions
clinical endpoint development
patient access intention
future interventional clinical trials - MACUSTAR
acceptable outcome measures
impact of visual loss
specific risk factors
in-depth assessment of structural abnormalities
novel approaches
central vision
regulatory agencies
structural biomarker extraction
corrected visual acuity
intermediate age-related macular degeneration
main cause of irreversible severe visual loss
available vision-related PROM
central grading centre
health technology assessment
major objective of MACUSTAR
subsequent grading
low luminance
significant advances
normal luminance
existing imaging technologies
multi-modal state-of-the-art high-resolution retinal imaging
scotopic microperimetry
HTA
Europe
treatment
quantifiable dark adaptation
automated image analysis
incidence
bodies
Bonn
GRADE
prevalence
BCVA
optimized combination
association
regards
participant
basis
good evidence
deep phenotyping
current demographic trends
measurement characteristics
UKB
impacts
background
Additional objectives
MIDs
functioning
prerequisite
important difference
patientsâ€™ life
payers
order
utility